Announcements Trials

Browse Landscape

Phase

Phase 2 49 Phase 1/2 15 Phase 1 15 Phase 3 13 Phase EARLY_PHASE1 2 Phase NA 1 Phase 4 1 Phase 2/3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 1

Interventions

Dexamethasone 13 Saline Solution 8 Bupivacaine 8 Bevacizumab 8 Tobacco Use Cessation Devices 7 Specimen Handling 7 Nivolumab 7 Magnetic Resonance Spectroscopy 7 Lenalidomide 7 Fluorouracil 7 pembrolizumab 6 Rituximab 6 Prednisone 6 Letrozole 6 Carboplatin 6 Propofol 5 Human Papillomavirus Recombinant Vaccine nonavalent 5 trametinib 4 lenvatinib 4 dabrafenib 4 cabozantinib 4 anlotinib 4 Trastuzumab 4 Tamoxifen 4 Standard of Care 4 Sodium Chloride 4 Ropivacaine 4 Paclitaxel 4 Immune Checkpoint Inhibitors 4 Esomeprazole 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 4 × Filgrastim × 1 year × Clear all

NCT05753618 2026-02-09

REaCT-OGF

Ottawa Hospital Research Institute

Phase 4 Recruiting

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡